Pre-vaccination vulnerability and suspected adverse events following HPV vaccination. A case-control study nested in the Danish national birth cohort.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
15 10 2021
Historique:
received: 27 06 2021
revised: 08 09 2021
accepted: 15 09 2021
pubmed: 26 9 2021
medline: 26 10 2021
entrez: 25 9 2021
Statut: ppublish

Résumé

Previous studies have indicated that girls experiencing suspected adverse events (AE) following HPV vaccination were more vulnerable prior to vaccination. However, no study has previously investigated differences in vulnerability using prospectively collected self-reported measures of vulnerability. The objective of this study therefore was to describe the distribution of biological and psychosocial indicators of vulnerability in girls referred to a hospital setting due to suspected adverse events and compare it with a sample of non-referred HPV vaccinated girls. The study was conducted as a case control study based within the Danish National Birth Cohort. Cases were defined as HPV vaccinated girls referred to a hospital setting between 2015 and 2017 due to suspected adverse events (n = 80), and 5 controls were randomly selected from the remaining source population, matched to cases on age at vaccination, region of residence and year of vaccination. The final study population consisted of 480 girls. Prior exposures were based on information gathered from an 11 year follow up of the DNBC and included information on self-rated health, frequent health complaints, medication use, bullying, stressful life events and physical activity. Conditional logistic regression analysis was used to estimate the association between each exposure and referral. The percentage of individuals in the exposed category of each exposure was generally higher for cases than controls. Particularly, the odds of being referred were higher for those with low self-rated health compared to high (OR [95%-CI] 2.43 [1.07-5.5]1), those being bullied (OR 3.19 [1.17-8.73]), and those who had taken medication (OR 2.22 [1.32-3.67]). Overall, these results indicated that girls experiencing suspected AE following HPV vaccination were more vulnerable prior to vaccination.

Identifiants

pubmed: 34561141
pii: S0264-410X(21)01232-9
doi: 10.1016/j.vaccine.2021.09.041
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6364-6369

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anna Melgaard (A)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: anme@au.dk.

Lene Wulff Krogsgaard (LW)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: l.krogsgaard@ph.au.dk.

Tina Hovgaard Lützen (TH)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: tina.lutzen@ph.au.dk.

Oleguer Plana-Ripoll (O)

National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus University, Denmark; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Denmark. Electronic address: opr@econ.au.dk.

Bodil Hammer Bech (BH)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: bhb@ph.au.dk.

Louise Krüger Hansen (LK)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark.

Charlotte Ulrikka Rask (CU)

Research Unit, Department of Child and Adolescent Psychiatry, Aarhus University Hospital, 8200 Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark. Electronic address: charrask@rm.dk.

Dorte Rytter (D)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: dr@ph.au.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH